- Home
- PETS vs KPTI Comparison
PETS vs KPTI Comparison
Compare PETS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- KPTI
- Stock Information
- Founded
- PETS 1996
- KPTI 2008
- Country
- PETS United States
- KPTI United States
- Employees
- PETS N/A
- KPTI N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- KPTI Health Care
- Exchange
- PETS Nasdaq
- KPTI Nasdaq
- Market Cap
- PETS 62.8M
- KPTI 54.4M
- IPO Year
- PETS N/A
- KPTI 2013
- Fundamental
- Price
- PETS $3.62
- KPTI $6.01
- Analyst Decision
- PETS Sell
- KPTI Strong Buy
- Analyst Count
- PETS 2
- KPTI 5
- Target Price
- PETS $3.35
- KPTI $61.00
- AVG Volume (30 Days)
- PETS 135.2K
- KPTI 85.6K
- Earning Date
- PETS 06-10-2025
- KPTI 05-20-2025
- Dividend Yield
- PETS N/A
- KPTI N/A
- EPS Growth
- PETS N/A
- KPTI N/A
- EPS
- PETS 0.02
- KPTI N/A
- Revenue
- PETS $247,010,000.00
- KPTI $145,237,000.00
- Revenue This Year
- PETS N/A
- KPTI $4.87
- Revenue Next Year
- PETS N/A
- KPTI $16.29
- P/E Ratio
- PETS $213.02
- KPTI N/A
- Revenue Growth
- PETS N/A
- KPTI N/A
- 52 Week Low
- PETS $2.90
- KPTI $3.51
- 52 Week High
- PETS $6.85
- KPTI $18.00
- Technical
- Relative Strength Index (RSI)
- PETS 53.72
- KPTI 51.12
- Support Level
- PETS $3.26
- KPTI $5.52
- Resistance Level
- PETS $3.74
- KPTI $7.90
- Average True Range (ATR)
- PETS 0.14
- KPTI 0.69
- MACD
- PETS 0.06
- KPTI 0.04
- Stochastic Oscillator
- PETS 80.95
- KPTI 24.73
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.